Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II docetaxel + ramucirumab in second-line metastatic/advanced gastric cancer (HGCSG1903)
jRCTs011200010Phase 2Completed
- Sponsor
- Hokkaido Gastrointestinal Cancer Study Group
- Start
- Feb 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and ramucirumab in gastric adenocarcinoma, sponsored by Hokkaido Gastrointestinal Cancer Study Group. Primary endpoint: Response rate. Started Feb 2021; status: completed.
02
Drugs
docetaxelramucirumab
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on jRCTs011200010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs011200010.